Graves' hyperthyroidism showing transient hypothyroidism during interferon therapy for chronic hepatitis type C

Endocrine Journal

Volumn 52, Issue 3, 2005, Pages 293-298

  Inoue, Atsushi ^a   Koizumi, Shigeki ^a   Matsuda, Akira ^a   Mizuo, Hitoshi ^a   Iriuda, Yoshihiro ^a   Ikota, Akemi ^b   Beniko, Mutsuo ^b   Kosugi, Takashi ^b   Matsuya, Kumiko ^c   Kunita, Haruhiko ^c   Mashio, Yasuo ^d  

^a Department of Surgery   (Japan)

^b Kin I Kyo Sapporo Hospital   (Japan)

^c Kin Ikyo Sapporo Nishiku Hospital   (Japan)

^d Kin ikyo Sapporo Clinic   (Japan)

Author keywords

Chronic hepatitis; Graves' disease; Interferon

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; TECHNETIUM 99M; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CHRONIC ACTIVE HEPATITIS; CHRONIC HEPATITIS; DRUG BLOOD LEVEL; GRAVES DISEASE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; MALE; SIDE EFFECT; THYROID DISEASE; THYROID FUNCTION; THYROIDITIS;

ADULT; CYTOKINES; GRAVES DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPOTHYROIDISM; IMMUNOGLOBULINS, THYROID-STIMULATING; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-BETA; MALE; THYROID FUNCTION TESTS; THYROID GLAND;

EID: 22344453819     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.52.293     Document Type: Article

References (28)

1. Ronnblom LE, Alm GV, Oberg KE (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115: 178-183.
2. Koizumi S, Mashio Y, Mizuo H, Matsuda A, Matsuya K, Mizumoto H, Ikota A, Beniko M, Iriuda Y (1995) Graves' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C. Intern Med 34: 58-60.
3. Furukawa S, Imai K, Matsubara T, Yone K, Yachi A, Okumura K, Yabuta K (1992) Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. Arthritis Rheum 35: 672-611.
4. Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, Martin S (1992) Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 41: 1668-1671.
5. Rothlein R, Czajkowski M, O'Neill MM, Marlin SD, Mainolfi E, Merluzzi VJ (1988) Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. J Immunol 141: 1665-1669.
6. Ayres RC, Neuberger JM, Shaw J, Joplin R, Adams DH (1993) Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines. Gut 34: 1245-1249.
7. Kasagi K, Konishi J, Arai K, Misaki T, Iida Y, Endo K, Torizuka K (1986) A sensitive and practical assay for thyroid-stimulating antibodies using crude immunoglobulin fractions precipitated with polyethylene glycol. J Clin Endocrinol Metab 62: 855-862.
8. Kasagi K (1998) Studies on the clinical application of TSBAb measurement using TSAb kit "Yamasa". Horumon To Rinsho 46: 913-924 (in Japanese).
9. Kricka LJ (1991) Chemiluminescent and bioluminescent techniques. Clin Chem 37: 1472-1481.
10. Schultz M, Muller R, von zur Muhlen A, Brabant G (1989) Induction of hyperthyroidism by interferon-alpha-2b. Lancet 24: 1452.
11. Burman P, Totterman TH, Oberg K, Karlsson FA (1986) Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab 63: 1086-1090.
12. Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH (1992) Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102: 2155-2160.
13. Nagayama Y, Ohta K, Tsuruta M, Takeshita A, Kimura H, Hamasaki K, Ashizawa K, Nakata K, Yokoyama N, Nagataki S (1994) Exacerbation of thyroid autoimmunity by interferon α treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 41: 565-512.
14. Golub SH (1984) Immunological and therapeutic effects of interferon treatment of cancer patients. Clin Immunol Allergy 4: 377.
15. Hanafusa T, Pujol-Borrell R, Chiovato L, Russell RC, Doniach D, Bottazzo GF (1983) Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity. Lancet 12: 1111-1115.
16. Jansson R, Karlsson A, Forsum U (1984) Intrathyroidal HLA-DR expression and T lymphocyte phenotypes in Graves' thyrotoxicosis, Hashimoto's thyroiditis and nodular colloid goiter. Clin Exp Immunol 58: 264-272.
17. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, Meyer zum Buschenfelde KH (1989) Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10: 24-28.
18. Daniels HM, Meager A, Eddleston AL, Alexander GJ, Williams R (1990) Spontaneous production of tumour necrosis factor α and interleukin-1β during interferon-α treatment of chronic HBV infection. Lancet 14: 875-877.
19. Nouri-Aria KT, Koskinas J, Tibbs CJ, Portmann BC, Williams R (1995) Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: association with disease activity and response to interferon α. Gut 36: 599-603.
20. Fukazawa H, Yoshida K, Kaise N, Kiso Y, Sayama N, Mori K, Kikuchi K, Aizawa Y, Rikimaru A, Abe K (1995) Intercellular adhesion molecule-1 (ICAM-1) in the sera of patients with Graves' disease: correlation with disease activity and treatment status. Thyroid 5: 373-377.
21. Kasagi K, Hidaka A, Endo K, Miyamoto S, Takeuchi R, Misaki T, Sakahara H, Konishi J (1993) Fluctuating thyroid function depending on the balance between stimulating and blocking types of TSH receptor antibodies: a case report. Thyroid 3: 315-318.
22. Miyauchi A, Amino N, Tamaki H, Kuma K (1988) Coexistence of thyroid-stimulating and thyroid-blocking antibodies in a patient with Graves' disease who had transient hypothyroidism. Am J Med 85: 418-420.
23. Chen FQ, Okamura K, Sato K, Kuroda T, Mizokami T, Fujikawa M, Tsuji H, Okamura S, Fujishima M (1996) Reversible primary hypothyroidism with blocking or stimulating type TSH binding inhibitor immunoglobulin following recombinant interferon-α therapy in patients with pre-existing thyroid disorders. Clin Endocrinol (Oxf) 45: 207-214.
24. Hayakawa T, Nagai Y, Ohsawa K, Taniguchi M, Koike N, Notsumata K, Nakamura S, Ikeda T, Kobayashi K (1997) Two cases of transiently TSBAb-positive hypothyroidism induced by interferon-alpha therapy for chronic hepatitis C. Endocr J 44: 541-546.
25. Kasagi K, Hidaka A, Nakamura H, Takeuchi R, Misaki T, Iida Y, Konishi J (1993) Thyrotropin receptor antibodies in hypothyroid Graves' disease. J Clin Endocrinol Metab 76: 504-508.
26. Tsuboi K, Katayama M, Yuasa R, Matoba H, Nagayama T, Ihara F, Ooya T, Matsuo K, Otsuka S, Miyachi Y (1998) Interferon-alpha-induced thyroid dysfunction in patients with chronic active hepatitis C: a transient, reversible and self-limited dysfunction. Intern Med 37: 27-31.
27. Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, Weissel M (1992) Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90: 363-367.
28. Vaidya B, Oakes EJ, Imrie H, Dickinson AJ, Perros P, Kendall-Taylor P, Pearce SH (2003) CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol (Oxf) 58: 732-735.